Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Adicet Bio, Inc. (ACET : NSDQ)
 
 • Company Description   
Adicet Bio Inc. is a biotechnology company. It engages in discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases. Adicet Bio Inc., formerly known as RESTORBIO INC, is based in Calif.

Number of Employees: 152

 
 • Price / Volume Information   
Yesterday's Closing Price: $0.61 Daily Weekly Monthly
20 Day Moving Average: 359,192 shares
Shares Outstanding: 82.71 (millions)
Market Capitalization: $50.21 (millions)
Beta: 1.62
52 Week High: $1.70
52 Week Low: $0.45
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week -19.85% -23.41%
12 Week 13.03% -3.45%
Year To Date -36.90% -40.90%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
131 DARTMOUTH STREET 3RD FLOOR
-
BOSTON,MA 02116
USA
ph: 650-503-9095
fax: -
abowdidge@adicetbio.com http://www.adicetbio.com
 
 • General Corporate Information   
Officers
Chen Schor - President; Chief Executive Officer and Director
Nick Harvey - Chief Financial Officer
Jeffrey Chodakewitz - Director
Steve Dubin - Director
Carl L. Gordon - Director

Peer Information
- (-)
- (-)
- (-)
- (-)
- (-)
- (-)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 007002108
SIC: 2834
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/25
Next Expected EPS Date: 08/12/25
Share - Related Items
Shares Outstanding: 82.71
Most Recent Split Date: 9.00 (0.14:1)
Beta: 1.62
Market Capitalization: $50.21 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $-0.31 Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $-1.13 Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: 3.00 Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 08/12/25  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: 0.31
Price/Cash Flow: -
Price / Sales: -
EPS Growth
vs. Year Ago Period: 11.43%
vs. Previous Quarter: 3.12%
Sales Growth
vs. Year Ago Period: -%
vs. Previous Quarter: -%
ROE
06/30/25 - -
03/31/25 - -59.05
12/31/24 - -52.52
ROA
06/30/25 - -
03/31/25 - -50.66
12/31/24 - -45.57
Current Ratio
06/30/25 - -
03/31/25 - 9.34
12/31/24 - 9.29
Quick Ratio
06/30/25 - -
03/31/25 - 9.34
12/31/24 - 9.29
Operating Margin
06/30/25 - -
03/31/25 - -
12/31/24 - -
Net Margin
06/30/25 - -
03/31/25 - -
12/31/24 - -
Pre-Tax Margin
06/30/25 - -
03/31/25 - -
12/31/24 - -
Book Value
06/30/25 - -
03/31/25 - 1.95
12/31/24 - 2.26
Inventory Turnover
06/30/25 - -
03/31/25 - -
12/31/24 - -
Debt-to-Equity
06/30/25 - -
03/31/25 - 0.00
12/31/24 - 0.00
Debt-to-Capital
06/30/25 - -
03/31/25 - 0.00
12/31/24 - 0.00
 

Powered by Zacks Investment Research ©